BioSpace News Archive

Genetic testing company Seq2Know is now offering Celiac disease testing.

College enrollment and degrees awarded in STEM subjects are on the rise, and with more courses come more assignments that need to be graded. Turnitin has acquired Gradescope, an assessment platform that reduces the time associated with grading in college courses via an optimized online workflow and clever application of artificial intelligence.

Since its inception, Paragon 28® has obsessed over every aspect of foot and ankle surgery.

Signature Performance, Inc. announced today it is joining Cerner, a global leader in health care technology, and other industry leaders and innovators to help make seamless care available to the nation’s veterans.

ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today announced additional positive Phase 3 data from the IMPLANT 2 trial of its oral, oxytocin receptor antagonist, Nolasiban in patients undergoing IVF procedures, as well as future development plans following receipt of EU regulatory feedback.

The addition of MD brings more than $49 billion in assets under management and administration to Scotiabank’s Wealth Management business

A new cancer treatment offered at MemorialCare Long Beach Medical Center is helping to protect patients’ hearts from the effects of radiation therapy.

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, today announced that the Company will host an Investor Day on Tuesday, October 23, 2018 from 12:00 p.m. to 2:00 p.m. in New York City.

Corvus Pharmaceuticals, Inc. today announced the publication of results of preclinical studies of CPI-444 demonstrating that it induces dose dependent anti-tumor responses as a monotherapy and in combination with anti-PD-1, anti-PD-L1 and anti-CTLA-4 therapies.

The Janssen Pharmaceutical Companies of Johnson & Johnson unveils new 96-week data for SYMTUZA™ (darunavir 200 mg, cobicistat 150 mg, emtricitabine 200mg, and tenofovir alafenamide 10 mg; D/C/F/TAF), a single-tablet regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) in treatment-naïve and certain virologically suppressed adults, in a presentation at IDWeek 2018 in San Francisco, CA.